<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The European Scleroderma Trials and Research group (EUSTAR) Task Force for the Development of Revised Activity Criteria For Systemic Sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Gabriele</forename><surname>Valentini</surname></persName>
							<email>gabriele.valentini@unina2.it</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="institution">Second University of Naples</orgName>
								<address>
									<settlement>Rheumatology Section, Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michele</forename><surname>Iudici</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="institution">Second University of Naples</orgName>
								<address>
									<settlement>Rheumatology Section, Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><forename type="middle">A</forename><surname>Walker</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Basel University</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Veronika</forename><forename type="middle">K</forename><surname>Jaeger</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Basel University</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Murray</forename><surname>Baron</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Division of Rheumatology</orgName>
								<orgName type="institution" key="instit1">Jewish General Hospital</orgName>
								<orgName type="institution" key="instit2">McGill University</orgName>
								<address>
									<postCode>H3T 1E2</postCode>
									<settlement>Montreal</settlement>
									<region>Quebec</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">4Department of Rheumatology</orgName>
								<orgName type="institution">Octubre University Hospital</orgName>
								<address>
									<addrLine>12 de</addrLine>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Carreira</surname></persName>
						</author>
						<author>
							<persName><forename type="first">László</forename><surname>Czirják</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Rheumatology and Immunology</orgName>
								<orgName type="department" key="dep2">Medical Centre</orgName>
								<orgName type="institution">University of Pécs</orgName>
								<address>
									<settlement>Pécs</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Medicine</orgName>
								<orgName type="department" key="dep2">Royal Free Campus</orgName>
								<orgName type="laboratory">Centre for Rheumatology and Connective Tissue Disease</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<postCode>NW3 2QG</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oliver</forename><surname>Distler</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Division of Rheumatology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Hachulla</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Internal Medicine Department</orgName>
								<orgName type="institution" key="instit1">Claude Huriez Hospital</orgName>
								<orgName type="institution" key="instit2">Lille University</orgName>
								<address>
									<settlement>Lille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arianne</forename><surname>Herrick</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Centre for Musculoskeletal Research</orgName>
								<orgName type="institution" key="instit1">NIHR Manchester Musculoskeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit2">The University of Manchester</orgName>
								<orgName type="institution" key="instit3">Manchester Academic Health Science Centre</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Otylia</forename><surname>Kowal-Bielecka</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Rheumatology and Internal Medicine</orgName>
								<orgName type="institution">Medical University of Bialystok</orgName>
								<address>
									<settlement>Bialystok</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">11Department of Medicine</orgName>
								<orgName type="institution" key="instit1">St. Joseph&apos;s Health Care</orgName>
								<orgName type="institution" key="instit2">University of Western Ontario</orgName>
								<address>
									<postCode>N6A 4V2</postCode>
									<settlement>London</settlement>
									<region>Ontario</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janet</forename><surname>Pope</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Müller- Ladner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><surname>Riemekasten</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution" key="instit1">Justus-Liebig University Giessen</orgName>
								<orgName type="institution" key="instit2">Kerckhoff-Klinik</orgName>
								<address>
									<settlement>Bad Neuheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Clinic for Rheumatology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jerome</forename><surname>Avouac</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marc</forename><surname>Frerix</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution" key="instit1">Justus-Liebig University Giessen</orgName>
								<orgName type="institution" key="instit2">Kerckhoff-Klinik</orgName>
								<address>
									<settlement>Bad Neuheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Suzana</forename><surname>Jordan</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Division of Rheumatology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tünde</forename><surname>Minier</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Rheumatology and Immunology</orgName>
								<orgName type="department" key="dep2">Medical Centre</orgName>
								<orgName type="institution">University of Pécs</orgName>
								<address>
									<settlement>Pécs</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elise</forename><surname>Siegert</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">University Hospital Charité</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Voon</forename><forename type="middle">H</forename><surname>Ong</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Medicine</orgName>
								<orgName type="department" key="dep2">Royal Free Campus</orgName>
								<orgName type="laboratory">Centre for Rheumatology and Connective Tissue Disease</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<postCode>NW3 2QG</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Serena</forename><surname>Vettori</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="institution">Second University of Naples</orgName>
								<address>
									<settlement>Rheumatology Section, Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Affiliations</surname></persName>
							<affiliation key="aff14">
								<orgName type="laboratory">INSERM U1016 and CNRS UMR8104</orgName>
								<orgName type="institution" key="instit1">Cochin Institute</orgName>
								<orgName type="institution" key="instit2">Paris Descartes University</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Prof</roleName><forename type="middle">Gabriele</forename><surname>Valentini</surname></persName>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Department of Clinical and Experimental Medicine</orgName>
								<orgName type="institution">Second University of Naples</orgName>
								<address>
									<settlement>Rheumatology Section, Naples</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="institution">Italy. II Policlinico</orgName>
								<address>
									<addrLine>Edificio 3, Via Pansini 5</addrLine>
									<postCode>80131</postCode>
									<settlement>Napoli</settlement>
									<country key="IT">Italia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The European Scleroderma Trials and Research group (EUSTAR) Task Force for the Development of Revised Activity Criteria For Systemic Sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">F4ED6D23799522F4034CA85FDF94C0A1</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:47+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Systemic Sclerosis</term>
					<term>Disease activity</term>
					<term>Autoimmune disease</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>IRB approval was obtained previously as EULAR/EUSTAR data were used that were collected previously on patients who had signed informed consent.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The assessment of patients with systemic sclerosis (SSc) should address different disease aspects: diagnosis and fulfilment of classification criteria, extent of organ involvement, activity (the reversible part of the disease process), damage (the irreversible part of the disease process), prognosis prediction, outcome, and response to treatment.</s><s><ref type="bibr" target="#b0">[1]</ref> Defining disease activity in SSc cannot be done using a single variable and it is challenging for a number of reasons: first, patients can present with an indolent course, irrespective of whether or not they belong to either of the two disease subsets, i.e., diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc); <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b6">[6]</ref> second, SSc flares can be difficult to separate from quiescent disease; <ref type="bibr" target="#b0">[1]</ref>third, the two main morphological manifestations of the disease (interstitial fibrosis and vascular occlusion) may reflect both activity and damage and finally, validated biological markers reflecting disease activity are still lacking.</s><s><ref type="bibr" target="#b7">[7]</ref> In 2001, the European Scleroderma Study Group (EScSG) in an analysis of the clinical charts of 290 patients from 19 European SSc centres, identified 11 disease activity variables and developed a preliminary activity index.</s><s><ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b9">9]</ref> The construct validity of the index was first verified by the jackknife technique (i.e., assessing the dispersion of the correlation coefficients calculated by removing out 1 patient at a time), <ref type="bibr" target="#b10">[10]</ref> then confirmed by calculating the correlations between the index and the rank of disease activity assigned by 4 experts to 30 charts, selected to represent different degrees of disease activity.</s><s><ref type="bibr" target="#b11">[11]</ref> This index was subsequently endorsed by EUSTAR and has been used to assess disease activity in 149 studies.</s><s><ref type="bibr" target="#b12">[12]</ref>Its criterion validity is supported by its correlation with the physician global assessment of activity of the Canadian Scleroderma Research group (CSRG), <ref type="bibr" target="#b13">[13]</ref> its association with anti-topoisomerase1 titre, <ref type="bibr" target="#b14">[14]</ref> and its role as the main predictor of the scleroderma phenotype (presenting a higher procollagen transcription) of skin fibroblasts from SSc patients.</s><s><ref type="bibr" target="#b15">[15]</ref> However, it has some limitations due to the procedure underlying its development.</s><s>In fact, it most patients had a long disease duration and the number of missing values was high.</s><s>Moreover, the face validity of hypocomplemaentemia has been questioned since the complement fixation is not thought to be important in SSc.</s><s><ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b18">17]</ref>.</s><s>Finally, it was not validated on an independent cohort.</s></p><p><s>Here, we present the results of a EUSTAR study devoted to revise the original activity index in order to improve and validate it.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Derivation study</head><p><s>The Study Coordinator selected 97 clinical charts from patients included in the EUSTAR database.</s><s><ref type="bibr" target="#b4">[5]</ref>The selection was carried out in order to identify patients fulfilling the 1980 ACR criteria for the classification of SSc; <ref type="bibr" target="#b19">[18]</ref> followed in SSc referral centres in order to reduce the number of missing values; and representing one of the following disease subgroups: early dcSSc, late dcSSc, early lcSSc, and late lcSSc.</s><s>Early disease was defined a disease duration ≤ 3 years from the onset of the first non-Raynaud symptom.</s><s><ref type="bibr" target="#b20">[19]</ref> Three clinical investigators (YA, CD and OK-B) from centres other than those from which the patients charts were derived, assigned a disease activity score on a 0-10 scale to each chart.</s><s>The reliability of this scoring system was assessed by the evaluation of the Interclass Correlation Coefficient (ICC).</s><s>The median disease activity score was used as the "gold standard" to identify items significantly associated to disease activity.</s></p><p><s>To this aim, the study coordinator selected from the items listed in the EUSTAR chart, <ref type="bibr" target="#b4">[5]</ref>the following 18 thought to have face validity as activity variables 1)anamnestic:Δ-skin, Δvascular, Δheart/lung worsening (i.e.</s><s>worsening, as evaluated by the patient during the month before enrolment, of skin induration, Raynaud's phenomenon and/or digital ischemic ulcers and dyspnea and/or palpitations, respectively); 2) clinical: active digital ulcers; modified Rodnan skin score(mRss); tendon friction rubs(TFR); muscle weakness; arthritis; 3) laboratory: C-Reactive Protein (CRP) elevation; erythrocyte sedimentation rate (ESR)/h value; hypocomplementemia; creatin-kinase(CK) elevation; proteinuria; 4) functional and imaging : systolic Pulmonary Arterial Pressure(sPAP) and pericardial effusion at echocardiography; ground glass and lung fibrosis at lung High Resolution Computed Tomography (HRCT); Forced Vital Capacity(FVC); Diffusing Lung capacity for carbon monoxide-single breath (DLCO).</s></p><p><s>Subsequently, we performed an univariate linear regression analysis to search for significant associations between each of the selected items and the median disease activity score given by the 3 experts.</s><s>Cut-off values for sPAP, FVC and DLCO were derived from literature.</s><s><ref type="bibr" target="#b21">[20]</ref><ref type="bibr" target="#b22">[21]</ref><ref type="bibr" target="#b23">[22]</ref> The items significantly associated with gold standard in univariate analysis, were all entered in a multivariate linear regression analysis to identify the set of variables independently associated with the "gold standard".</s><s>As far as the remaining 2 continuous variables (mRss and ESR) , we made a number of attempts devoted to both identify the cut off point most significantly associated with the gold standard (highest R2; lowest p)to construct a model with the highest sum of sensitivity and specificity .Each variable found to be significantly associated in multivariate analysis was assigned a weight corresponding to beta coefficient adjusted in order to construct a 10-point weighted activity index.</s></p><p><s>Two other investigators (LC and GV), who were unaware of the values assigned on the 0-10 scale, evaluated each of the 97 charts as inactive (corresponding to no need to change treatment and requiring a follow-up after six months-1 year), or moderately active (corresponding to no need to change treatment and a three-six-monthly follow-up), or active (needing treatment intensification and one-three-monthly follow-up), or very active (requiring hospitalization for active disease).The reliability of this system was assessed by the evaluation of Cohen's K.</s><s>The charts that had received a discordant evaluation by the 2 investigators were resent to them for a reassessment devoted to find an agreement.</s></p><p><s>For each patient the overall disease activity was calculated summing the scores of the new index.</s></p><p><s>The cut-off value presenting the highest sum of sensitivity and specificity in separating patients with active-very active disease from those with inactive-moderately active condition was identified by a receiver operating (ROC) curve.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Validation study</head><p><s>The new index was validated on 60 patients recruited from the same database and selected in order to satisfy the following aspects: 1) fulfilling 2013 ACR/EULAR criteria for the classification of SSc; <ref type="bibr" target="#b24">[23]</ref>2) belonging to patients recruited at SSc centres with SSc expertise in whom capillaroscopy had been performed and the pattern defined according to Cutolo et al.; <ref type="bibr" target="#b25">[24]</ref> 3) being representative of one of the following disease subgroups, as described above: early dcSSc, late dcSSc, early lcSSc, and late lcSSc.</s><s>The 60 charts were assessed for disease activity on a 0-10 scale by three different investigators (PC,AH, JP) and defined as inactive, moderately active, active, and very active by other two investigators (MB and EH), all of whom unaware of the derived index.</s><s>The reliability of the two scoring systems was assessed by ICC and Κ statistics respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes of the index over time and its relationships to summed Medsger severity score</head><p><s>In order to furtherly validate the index, we assessed the changes in the activity index detected in patients from either derivation or validation cohorts in a follow-up visit at least 6 months apart and compared it with the changes in the summed Medsger severity score <ref type="bibr" target="#b26">[25]</ref>, that is a validated measure of disease severity in observational studies.</s><s><ref type="bibr" target="#b27">[26]</ref> We undertook this approach by considering that severity reflects both activity and damage and its change, being damage irreversible, can only depend on changes in the activity part of the disease process.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Derivation study</head><p><s>Table <ref type="table" target="#tab_0">1</ref> lists the main epidemiological, serological and clinical features of the 97 patients considered in the derivation part of this study.</s><s>All of the patients also satisfied 2013 ACR/ EULAR criteria.</s><s>The ICC among the activity scores given by the three clinical experts was 0.786 indicating that either the median or the mean value could be considered consistent measures of disease activity and supporting the use of one of them as a gold standard.</s><s><ref type="figure">---------------------------------------------------------------------------------------------------------------------------------</ref>Table 2 lists the items, out of the 19 selected, that resulted to be associated to the median value of the three 0-10 scores,in univariate linear regression analysis.</s><s>---------------------------------------------------------------------------------------------------------------------------------It is notable that no finding detected at high resolution computed tomography of the lung was associated to the gold standard.</s><s>However, the extent of lung involvement is not defined in the EUSTAR chart.</s></p><p><s>With single exceptions (e.g.</s><s>tendon friction rubs for lcSSc), the same items were also associated with the gold standard in each of the 2 subsets as well as in early and late disease (data not shown).After a number of attempts, we identified a mRss&gt; 18 and a ESR &gt; 50 mm/h as the cut off points most significantly associated with the gold standard (highest R2; lowest p), i.e. the value corresponding to the highest association of the variable in univariate analysis.</s><s>These values were entered in multivariate analysis along with the other items resulted to be associated with the gold standard.</s></p><p><s>Table <ref type="table" target="#tab_2">3</ref> lists the items resulted to be associated to the gold standard in multiple regression analysis and the respective weight that was assigned depending on the β values of the regression model, in order to construct a 10-point index.</s><s>The assessment of disease activity on the Likert scale was the same (i.e.</s><s>either inactive/moderately active or active/very active) in 91 patients; differed in 6 (Cohen's K=0.851).</s><s>In these 6 patients an agreement was reached after a re-evaluation of each chart that had given a discrepant evaluation.</s><s>Out of the 97 SSc patients, 57 were considered to be inactive to moderately active; 40 active to very active.</s></p><p><s>Figure <ref type="figure">1</ref> shows the ROC curve exploring the best cut off value discriminating between inactive-moderately active disease (no treatment change needed) and active-very active disease.</s></p><p><s>A value≥2.5 resulted to have the maximal sum of sensitivity ( 80.0% ;95%CI 64.4-90.9)</s><s>and specificity (91.2%;95%CI 80.7-97.1)</s><s>and was used to validate the index in the validation cohort</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Validation</head><p><s>Table <ref type="table" target="#tab_4">5</ref> shows the epidemiological, serological, capillaroscopic and clinical features of the additional set of 60 patients selected for the validation cohort.</s><s>Out of the 60 patients,47 also satisfied 1980 ACR criteria for the classification of the disease.</s></p><p><s>The scores given by the three raters were significantly correlated (ICC=0.749</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes of the index over time and its relationships to summed Medsger severity score</head><p><s>A follow-up visit made after 6-38 months (median 13) was available in 123 out of the 157 patients from either derivation and validation cohorts.</s><s>The calculated index unchanged in 36 patients, decreased in 59, increased in 28.The changes in the activity index resulted to be significantly correlated to those in the Medsger severity score in the 123 patients with a follow-up visit (Rho= 0.330; 95%CI 0.162-0.479,</s><s>p=0.0002), pointing out a significant relationship between the index and the course of disease severity.</s><s>In particular, at baseline, 43 out of the 123 patients had an activity index ≥ 2.5.</s><s>Twenty-two resulted to have an activity index &lt; 2.5 at the end of follow-up; out of them, 18 experienced a decrease (≥1 point), 4 a stable severity score.</s><s>On the other hand, among the remaining 80 patients with a baseline activity index &lt; 2.5, 8 resulted to develop an activity index ≥ 2.5 at the end of follow-up;out of them, 5 experienced an increase (≥1 point), 3 a stable severity score.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Using the multinational EUSTAR database, we have identified a preliminarily revised set of weighted items correlated to disease activity in patients with SSc.The 2001 EScSG study <ref type="bibr" target="#b8">[8,</ref><ref type="bibr" target="#b9">9]</ref> was based on the analysis of 290 patients, most of whom with longstanding disease and was affected by a high number of missing values ensuing in a low number of patients evaluable for most items.</s><s>In order to overcome these limitations, we only relied on charts from centres with a large and scientifically supported expertise and included a high proportion of patients with early disease.</s></p><p><s>The 97 patients selected for the derivation cohort present some aspects that deserve to be discussed.</s><s>First, 21 out the 48 patients with lcSSc were anti-Scl-70 positive.</s><s>Differences in the prevalence of anti-Scl-70 positivity among patients from different geographical regions have long been known: 29% of French patients with lcSSc vs 15% of American patients.</s><s><ref type="bibr" target="#b29">[27]</ref>.</s><s>Since all our patients came from European centres, this is an expected result.</s><s>Secondly, 2 dcSSc patients were anticentromere antibody positive.</s><s>However, this figure does not differ from the 5% prevalence of ACA in dcSSc reported by Steen et al. <ref type="bibr" target="#b30">[28]</ref>.Thirdly, 5 lcSSc patients presented tendon friction rubs.</s></p><p><s>Again, tendon friction rubs have been detected in 5% of lcSSc patients supporting the absence of any derived generalizability issues.</s><s><ref type="bibr" target="#b31">[29]</ref> The revised EUSTAR activity index differs from the original EScSG index in several aspects.</s></p><p><s>Hypocomplementemia and arthritis were not associated with disease activity in the present study, even in univariate analysis.</s><s>The role of hypocomplementemia in assessing SSc activity has been largely debated.</s><s><ref type="bibr" target="#b16">[16,</ref><ref type="bibr" target="#b18">17]</ref> Hudson et al. <ref type="bibr" target="#b32">[30]</ref> investigated 321 patients from the Canadian Scleroderma Research Group Registry, and found that hypocomplementemia was significantly associated with inflammatory myositis and vasculitis, and concluded that it may identify a subgroup of SSc patients who have overlap disease.</s><s>These data suggest that some patients enrolled in the</s></p><p><s>EScSG study <ref type="bibr" target="#b33">[31]</ref> were affected by SSc (all of them satisfied the 1980 ACR criteria) <ref type="bibr" target="#b19">[18]</ref> in overlap with other autoimmune systemic rheumatic diseases.</s><s>This aspect might also justify the exclusion of arthritis.</s></p><p><s>The revised EUSTAR index contains tendon friction rubs and increased serum CRP.</s><s>Tendon friction rubs were associated with diffuse and reduced survival in 1301 SSc patients.</s><s><ref type="bibr" target="#b34">[32]</ref> This item was predictive of worsening of skin fibrosis and scleroderma renal crisis in the EUSTAR cohort.</s><s><ref type="bibr" target="#b34">[32]</ref> CRP levels were increased in early disease and were associated with activity, skin, lung, kidney disease and poor survival in 1043 SSc patients from the CSRG Registry.</s><s><ref type="bibr" target="#b35">[33]</ref> Similarly to the EScSG activity index, the revised EUSTAR index contains mRSS, digital ulcers, and DLCO.</s><s>mRSS reflects the degree of skin sclerosis and has long been considered a measure of disease activity in SSc.</s><s><ref type="bibr" target="#b36">[34]</ref> One could argue that a decreasing mRss (e.g. from 24 to 18) might represent a reduced disease activity.</s><s>Nevertheless, the persistence of defined skin sclerosis is not consistent with inactive disease.</s><s>Digital ulcers are clearly related to vascular disease activity and have been recently found to predict the occurrence of new digital ulcers during follow-up and to be associated with cardiovascular morbidity and decreased survival.</s><s><ref type="bibr" target="#b37">[35]</ref> A decreased DLCO can depend on both vascular and interstitial lung disease.</s><s>In the absence of pulmonary hypertension, however, it has been found to provide the best overall estimate of HRCTmeasured lung fibrosis.</s><s><ref type="bibr" target="#b38">[36]</ref> Similarly to the EScSG activity index, the revised EUSTAR index contains -factors (namely Δskin).</s><s>Δ-items had been criticized because they can fail to capture persistent activity and are influenced by depression.</s><s><ref type="bibr" target="#b16">[16]</ref> Recently, however, patient assessment has been reported to be significantly correlated to mRSS, the Short Form 36 health survey physical component and skin involvement in the last month.</s><s><ref type="bibr" target="#b39">[37]</ref> In any case, the present index is less influenced by Δ items, which represented 45% of the 2001 index with respect to the 15% of the present one.</s></p><p><s>In the present study, three patients of the derivation cohort and 1 of the validation cohort had previously presented with scleroderma renal crisis, preventing the use of the revised EUSTAR activity index in that context.</s></p><p><s>Following the publication of the EScSG activity criteria, several attempts have been made to identify a set of criteria with an improved performance.</s><s>Diaconu et al. <ref type="bibr" target="#b40">[38]</ref>  They derived an eight-unweighted item index (scleroderma, mRSS, fatigue, exertional dyspnoea, DLCO, musculoskeletal symptoms, ESR and digital ulcers), performing similarly to the EScSG activity index <ref type="bibr" target="#b9">[9]</ref> in patients with either early or late disease.</s><s>Furthermore, Minier et al. <ref type="bibr" target="#b42">[39]</ref> identified two activity indexes (a 12-point extended index including  variables and a simplified 8.5point devoid of them) by investigating 131 consecutive patients at enrolment and 1 year later.</s></p><p><s>These patients were assessed using a standardised protocol including high-resolution computed tomography of the lung and echocardiography.</s><s>The authors confirmed the good construct validity of the original EScSG activity index and found a very good correlation both at baseline and after 1 year between both the extended and the simplified score and the original EScSG activity.</s></p><p><s>The SSc activity reported herein represents a step forward with respect to the EScSG activity index.</s><s><ref type="bibr" target="#b9">[9]</ref>.</s><s>First of all, unlike the EScSG activity index, it was validated on an independent cohort..Moreover, , the lower number and value of Δ-factors as well as the exclusion of disputable items like hypocomplementemia give it a greater face validity.</s><s>In addition, , the greater sensitivity detected in the validation cohort make it valuable in better charachterising the series investigated in observational studies.Finally, the revised EUSTAR activity index was found to parallel Medsger severity score over time.</s></p><p><s>Our study has some limitations.</s></p><p><s>First, the evaluation of predefined EUSTAR charts did not allow to capture either the extent of lung involvement, which has been found to be related to disease activity <ref type="bibr" target="#b43">[40]</ref> or any change in laboratory, physical or physiologic or radiological parameter, preventing any consideration of the changes of parameters like FVC/DLCO, -fibrosis at lung HRCT or acute phase reactants.</s><s>This</s></p><note type="other">Figure Legends.</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>asked 6</head><label>6</label><figDesc><div><p><s>SSc experts to evaluate 40 charts completed by clinical investigators from Nijmegen; 20 patients had early disease, not yet satisfying 1980 ACR classification criteria [18] and 20 had established disease.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .Figure 2 .</head><label>12</label><figDesc><div><p><s>Figure 1.</s><s>Receiver Operating Curve showing the relation between the value of the</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1 Epidemiological, serological, capillaroscopic and clinical features of the 97 SSc patients</head><label>1</label><figDesc><div><p><s>°° By ELISA on ANA positive sera; * ranging from small infarcts of the digital tips to digital gangrene; ** symmetric swelling and tenderness of the peripheral joints; *** as detected at physical examination; **** perception of leathery crepitus during motion of hands, wrists,elbows,shoulders, knees, ankles (both at anterior and posterior aspects) ***** thickening and induration of the skin as detected by physical examination; ^dysphagia and/or heartburn and/or bloating and/or vomiting and/or diarrhea and/or constipation; ^^either ground glass or interstitial fibrosis as detected at lung high resolution computed tomography;^^^ Forced vital capacity ^^^^diffusing lung for Carbon monoxide (single breath), ^^^^^as assessed by B-MODE Doppler echocardiography; ^^^^^^ diastolic dysfunction and/or cardiac blocks and/or palpitations and/or left ventricular Ejection Fraction&lt; 55% as assessed by EKG and B-MODE Doppler echocardiography, °rapidly deteriorating kidney failure with or without accelerated/malignant hypertension..</s></p></div></figDesc><table><row><cell>Patients</cell><cell>Whole</cell><cell>Early</cell><cell>Late</cell><cell>Early</cell><cell>Late</cell></row><row><cell></cell><cell>cohort</cell><cell>dcSSc</cell><cell>dcSSc</cell><cell>lcSSc</cell><cell>lcSSc</cell></row><row><cell></cell><cell>N=97</cell><cell>N=25</cell><cell>N=24</cell><cell>N=23</cell><cell>N=25</cell></row><row><cell>Sex (F/M)</cell><cell>77/20</cell><cell>15/10</cell><cell>21/3</cell><cell>18/5</cell><cell>23/2</cell></row><row><cell>Age (years), median; range</cell><cell>55 (21-89)</cell><cell>54 (21-70)</cell><cell>55 (25-75)</cell><cell cols="2">52 (23-89) 58 (41-75)</cell></row><row><cell>Disease duration ( from the first non-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Raynaud's manifestation):years</cell><cell>3 (0.5-47)</cell><cell>1 (0.5-3)</cell><cell>6 (3.1-18)</cell><cell>2 (0.5-3)</cell><cell>9 (4-47)</cell></row><row><cell>(median; range)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Antinuclear antibodies positive°</cell><cell>95 (98)</cell><cell>24</cell><cell>24</cell><cell>23</cell><cell>24</cell></row><row><cell>Anti-Scl-70 antibody positive°°</cell><cell>50 (51%)</cell><cell>15</cell><cell>14</cell><cell>11</cell><cell>10</cell></row><row><cell>Anti-centromere antibody positive°</cell><cell>17 (17%)</cell><cell>0</cell><cell>2</cell><cell>5</cell><cell>10</cell></row><row><cell>Anti-RNA polymerase III antibody</cell><cell>6 (6%)</cell><cell>2</cell><cell>3</cell><cell>0</cell><cell>1</cell></row><row><cell>positive°°</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Anti-U1RNP antibody positive°°</cell><cell>1 (1%)</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>0</cell></row><row><cell>Raynaud's phenomenon</cell><cell>97 (100%)</cell><cell>25</cell><cell>24</cell><cell>23</cell><cell>25</cell></row><row><cell>Active Digital Ulcers*</cell><cell>16 (16%)</cell><cell>4</cell><cell>7</cell><cell>2</cell><cell>3</cell></row><row><cell>Arthritis**</cell><cell>15 (15%)</cell><cell>5</cell><cell>4</cell><cell>0</cell><cell>6</cell></row><row><cell>Proximal muscle weakness***</cell><cell>29 (30%)</cell><cell>9</cell><cell>6</cell><cell>6</cell><cell>8</cell></row><row><cell>Tendon Friction Rubs(TFR)****</cell><cell>14 (14%)</cell><cell>6</cell><cell>3</cell><cell>4</cell><cell>1</cell></row><row><cell>Skin sclerosis******</cell><cell>92 (95%)</cell><cell>25</cell><cell>24</cell><cell>20</cell><cell>23</cell></row><row><cell>Esophageal, stomach and/or</cell><cell>66 (68%)</cell><cell>16</cell><cell>15</cell><cell>15</cell><cell>20</cell></row><row><cell>intestinal involvement^</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Interstitial lung disease (CT)^^</cell><cell>53/89 (59%)</cell><cell>13/25</cell><cell>17/24</cell><cell>10/18</cell><cell>13/22</cell></row><row><cell>FVC^^^, % of the predicted value</cell><cell>87.5±18.9</cell><cell>89.4±17.3</cell><cell>78.7±20.0</cell><cell>90.8±12.8</cell><cell>91.0±22.3</cell></row><row><cell>(mean±SD)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DLCO^^^^, % of the predicted</cell><cell>65.7±21.5</cell><cell>65.9±20.1</cell><cell>56.5±19.9</cell><cell>69.9±16.4</cell><cell>70.6±26.3</cell></row><row><cell>value(mean±SD)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Estimated systolic pulmonary artery</cell><cell>22 (23%)</cell><cell>4</cell><cell>5</cell><cell>6</cell><cell>7</cell></row><row><cell>pressure (sPAP)&gt;30 mmHg^^^^^</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Heart disease^^^^^^</cell><cell>45 (46%)</cell><cell>9</cell><cell>14</cell><cell>7</cell><cell>15</cell></row><row><cell>Scleroderma renal crisis (previous)°</cell><cell>3 (3%)</cell><cell>2</cell><cell>1</cell><cell>0</cell><cell>0</cell></row><row><cell>° By IF on Hep-2 cells;</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 2 Associations between each potential activity parameter and the gold standard in Univariate Regression Analysis</head><label>2</label><figDesc></figDesc><table><row><cell>Item</cell><cell>R 2 *</cell><cell>P</cell></row><row><cell>ESR</cell><cell>0.441</cell><cell>0.0001</cell></row><row><cell>Digital ulcers</cell><cell>0.294</cell><cell>0.0001</cell></row><row><cell>CRP&gt; 1 mg/dl</cell><cell>0.256</cell><cell>0.0001</cell></row><row><cell>mRss</cell><cell>0.238</cell><cell>0.0001</cell></row><row><cell>Δ-skin worsened</cell><cell>0.180</cell><cell>0.0001</cell></row><row><cell>Δ-vascular worsened</cell><cell>0.164</cell><cell>0.0001</cell></row><row><cell>Δ-heart/lung worsened</cell><cell>0.160</cell><cell>0.0001</cell></row><row><cell>CK elevation</cell><cell>0.127</cell><cell>0.0003</cell></row><row><cell>TFR</cell><cell>0.126</cell><cell>0.0004</cell></row><row><cell>FVC&lt;80 % of predicted</cell><cell>0.114</cell><cell>0.0007</cell></row><row><cell>Muscle weakness</cell><cell>0.094</cell><cell>0.002</cell></row><row><cell>DLCO&lt;70% of predicted</cell><cell>0.085</cell><cell>0.003</cell></row><row><cell>Dyspnea and/or palpitations</cell><cell>0.057</cell><cell>0.017</cell></row><row><cell>sPAP&gt;30 mmHg</cell><cell>0.052</cell><cell>0.023</cell></row><row><cell>Arthritis</cell><cell>0.029</cell><cell>0.094</cell></row><row><cell>Lung fibrosis at lung HRCT</cell><cell>0.017</cell><cell>0.223</cell></row><row><cell>Hypocomplementemia</cell><cell>0.005</cell><cell>0.478</cell></row><row><cell>Ground glass at lung HRCT</cell><cell>0.0005</cell><cell>0.835</cell></row></table><note><p><s>*R-squared coefficient ;ESR.</s><s>erythrocyte sedimentation rate;CRP.</s><s>C-reactive protein; mRss.</s><s>modified Rodnan skin score; CK. creatin kinase; TFR.</s><s>tendon friction rubs; FVC.</s><s>forced vital capacity; DLCO.</s><s>diffusing lung for Carbon monoxide (single breath), HRCT.</s><s>high resolution computed tomography;</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 Items found to be associated with the activity gold standard in multiple linear regression analysis and the resulting 2016 preliminary activity index</head><label>3</label><figDesc></figDesc><table><row><cell>Items</cell><cell>beta regression</cell><cell>p</cell><cell>Weight</cell></row><row><cell></cell><cell>coefficient (SE)</cell><cell></cell><cell></cell></row><row><cell>Δ-skin</cell><cell>1.00 (0.313)</cell><cell>0.001</cell><cell>1.5</cell></row><row><cell>Digital ulcers</cell><cell>1.078 (0.373)</cell><cell>0.004</cell><cell>1.5</cell></row><row><cell>Modified Rodnan skin score &gt; 18</cell><cell>1.040 (0.319)</cell><cell>0.001</cell><cell>1.5</cell></row><row><cell>Tendon friction rubs</cell><cell>1.408 (0.317)</cell><cell>0.0001</cell><cell>2.25</cell></row><row><cell>C-reactive protein &gt; 1 mg/dl</cell><cell>1.401 (0.285)</cell><cell>0.0001</cell><cell>2.25</cell></row><row><cell>DLCO &lt; 70% of the predicted value</cell><cell>0.527 (0.259)</cell><cell>0.044</cell><cell>1.0</cell></row><row><cell>TABLE 4</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">REVISED EUSTAR INDEX</cell><cell></cell><cell></cell></row><row><cell>ITEM</cell><cell></cell><cell>WEIGHT</cell><cell></cell></row><row><cell>Δ-skin</cell><cell></cell><cell>1.5</cell><cell></cell></row><row><cell>Digital ulcers</cell><cell></cell><cell>1.5</cell><cell></cell></row><row><cell>Modified Rodnan skin score &gt; 18</cell><cell></cell><cell>1.5</cell><cell></cell></row><row><cell>or for</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Modified Rodnan skin score up to 18</cell><cell>Scorex 0.084</cell><cell></cell></row><row><cell>Tendon friction rubs</cell><cell></cell><cell>2.25</cell><cell></cell></row><row><cell>C-reactive protein &gt; 1 mg/dl</cell><cell></cell><cell>2.25</cell><cell></cell></row><row><cell>DLCO &lt; 70% of the predicted value</cell><cell></cell><cell>1.0</cell><cell></cell></row></table><note><p><s>SE. standard error; DLCO.Diffusing lung capacity for carbon monoxydeSince amRss lower than 18 can also reflect active disease, in the final index we considered a formulain which the highest possible value that was associated with the cut off point found to be most significantly associated with the gold standard.</s><s>In detail, each mRss score lower than 18 can contribute to the overall activity score according to the following formula: mRss score x 0.084.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>Out of the 60 patients, 37 were considered to be inactive to moderately active, 23 active to very active.</s><s>An index ≥2.5 identified active/very active disease as defined by</s></p></div></figDesc><table><row><cell>MB and EH with a 73.9% (95%CI 51.6-89.8) sensitivity and 78.3% (95%CI 61.8-90.2)</cell></row><row><cell>specificity.Performing the validation process in the 47 patients also satisfying 1980 classification</cell></row><row><cell>criteria, gave very similar results. In this cohort, a EScSG activity index ≥3 identified active disease</cell></row><row><cell>with a 52.2% sensitivity and 89.1% specificity.</cell></row></table><note><p><s>).</s><s>Moreover, their median values were significantly correlated to the respective calculated indices (Rho=0.772,</s><s>95%CI 0.644-0.857;</s><s>p&lt;0.0001).The early capillaroscopic pattern was associated with the gold standard (R 2 =0.07; p=0.029).</s><s>Nevertheless, adding it to the other items (Δ-skin; digital ulcers; modified Rodnan skin score &gt;18; tendon friction rubs; C-reactive protein &gt;1 mg/dl; DLCO &lt; 70% of the predicted value) in multivariate regression analysis, did not improve the performance of the index The evaluations on the Likert scale were consistent (i.e.</s><s>either inactive/moderately active or active/very active) in 46 patients; differed in 14 (Cohen's K=0.525).</s><s>In these 14 patients an agreement was reached.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE 5 Epidemiological, serological, capillaroscopic and clinical features of the 60SSc patients analyzed in the validation cohort</head><label>5</label><figDesc></figDesc><table><row><cell>Patients</cell><cell>Whole</cell><cell>Early</cell><cell>Late</cell><cell>Early</cell><cell>Late</cell></row><row><cell></cell><cell>series</cell><cell>dcSSc</cell><cell>dcSSc</cell><cell>lcSSc</cell><cell>lcSSc</cell></row><row><cell></cell><cell>n=60</cell><cell>n=16</cell><cell>n=14</cell><cell>n=16</cell><cell>n=14</cell></row><row><cell>Sex (F/M)</cell><cell>50/10</cell><cell>12/4</cell><cell>13/1</cell><cell>15/1</cell><cell>10/4</cell></row><row><cell>Age (years), median; range</cell><cell>56 (24-81)</cell><cell cols="4">51.5 (24-75) 59.5 (33-68) 56 (25-80) 58 (44-81)</cell></row><row><cell>Disease duration from 1 st non-Raynaud</cell><cell>2 (0-35)</cell><cell>1.5 (0-3)</cell><cell>13.5 (4-35)</cell><cell>1 (0-2)</cell><cell>8.5 (4-35)</cell></row><row><cell>manifestation (years), median; range</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Antinuclear antibodies positive</cell><cell>58 (97%)</cell><cell>15</cell><cell>13</cell><cell>16</cell><cell>14</cell></row><row><cell>Anti-Scl-70 antibody positive</cell><cell>24 (40%)</cell><cell>8</cell><cell>8</cell><cell>5</cell><cell>3</cell></row><row><cell>Anti-centromere antibody positive</cell><cell>15 (25%)</cell><cell>0</cell><cell>2</cell><cell>6</cell><cell>7</cell></row><row><cell>Anti-RNA polymerase I-III antibody</cell><cell>9/56 (16%)</cell><cell>3/13</cell><cell>3/13</cell><cell>2</cell><cell>1</cell></row><row><cell>positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Anti-U1RNP antibody positive</cell><cell>1/55 (2%)</cell><cell>0/13</cell><cell>0/12</cell><cell>0/16</cell><cell>1</cell></row><row><cell>Scleroderma pattern on nailfold</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>capillaroscopy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Early</cell><cell>13</cell><cell>1</cell><cell>1</cell><cell>6</cell><cell>5</cell></row><row><cell>Active</cell><cell>23</cell><cell>9</cell><cell>3</cell><cell>5</cell><cell>6</cell></row><row><cell>Late</cell><cell>19</cell><cell>3</cell><cell>8</cell><cell>5</cell><cell>3</cell></row><row><cell>Raynauds' phenomenon</cell><cell>59 (98%)</cell><cell>16</cell><cell>14</cell><cell>15</cell><cell>14</cell></row><row><cell>Active Digital Ulcers</cell><cell>14 (23%)</cell><cell>4</cell><cell>5</cell><cell>3</cell><cell>2</cell></row><row><cell>Arthritis</cell><cell>13 (21%)</cell><cell>3</cell><cell>2</cell><cell>4</cell><cell>4</cell></row><row><cell>Proximal muscle weakness</cell><cell>6 (10%)</cell><cell>1</cell><cell>3</cell><cell>1</cell><cell>1</cell></row><row><cell>Tendon Friction Rubs (TFR)</cell><cell>4 (7%)</cell><cell>2</cell><cell>1</cell><cell>1</cell><cell>0</cell></row><row><cell>Skin fibrosis</cell><cell>51 (85%)</cell><cell>16</cell><cell>13</cell><cell>11</cell><cell>11</cell></row><row><cell>Esophageal, stomach and/or intestinal</cell><cell>40 (67%)</cell><cell>12</cell><cell>11</cell><cell>11</cell><cell>6</cell></row><row><cell>involvement</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Interstitial lung disease ( CT)</cell><cell>38/55 (69%)</cell><cell>10/14</cell><cell>9/12</cell><cell>6</cell><cell>6/13</cell></row><row><cell>Estimated sPAP&gt;30 mmHg</cell><cell>9/52 (17%)</cell><cell>3/12</cell><cell>1/13</cell><cell>4/13</cell><cell>1</cell></row><row><cell>Heart disease</cell><cell>26 (43%)</cell><cell>4</cell><cell>7</cell><cell>8</cell><cell>7</cell></row><row><cell>Scleroderma renal crisis (previous)</cell><cell>1 (2%)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1</cell></row><row><cell cols="4">CT. computed tomography. sPAP. systolic pulmonary arterial pressure</cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>aspect can have prevented the inclusion of these items.</s><s>In that regard, however, one should consider the possible unavailability of some previous values and the need to assess disease activity at the first patient visit.</s><s>Secondly, no relevant biomarker was investigated.</s><s>This limitation could be approached in the future by a collaborative multicentre study including the assessment of parameters not included in the EUSTAR chart..Finally, the lower specificity with respect to the EScSG activity index in the validation cohort requires a careful evaluation in the clinical setting e.g. the patient with a respiratory infection presenting high CRP and low DLCO, who would be considered active according to the index, but is suffering from an unrelated condition..</s></p><p><s>In conclusion, the revised EUSTAR activity index is feasible, presents face, construct and content validity and represents a step forward to the so far widely used EScSG activity index.Future collaborative, prospective studies are needed to further improve its performance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Contributors</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The assessment of the patient with Systemic Sclerosis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autoimmunity Rev</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="370" to="376" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Ferri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cozzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine (Baltimore)</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="139" to="153" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Hachulla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gressin</surname></persName>
		</author>
		<author>
			<persName><surname>Guillevinl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="3792" to="3800" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hunzelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Genth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Krieg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1185" to="1192" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tyndall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Czirják</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="754" to="763" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Prediction of pulmonary complications and longterm survival in systemic sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Nihtyanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">H</forename><surname>Ong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheumatol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1625" to="1635" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Biomarkers in systemic sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Jimenez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomark Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="133" to="147" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Rossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="592" to="598" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score</title>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Angelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Rossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="904" to="905" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">The jackknife and the bootstroop</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tu</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1995">1995</date>
			<publisher>Springer</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria</title>
		<author>
			<persName><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bencivelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bombardieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AnnRheumDis</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="901" to="903" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<ptr target="http://scholar.google.it/citationsview_op=view_citation&amp;hl=it&amp;user=3z2zFpUAAAAJ&amp;citation_for" />
		<title level="m">_view=3z2zFpUAAAAJ:9yKSN-GCB0IC. Accessed on</title>
				<imprint>
			<date type="published" when="2015-09">September 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The Canadian Scleroderma Research Group et al. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)</title>
		<author>
			<persName><forename type="first">X</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><surname>Pope</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatol Int</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1205" to="1210" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hanke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dahnrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Bruchner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Therapy</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">R28</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Predictors of the scleroderma phenotype in fibroblasts from systemic sclerosis patients</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="160" to="168" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Steele</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Update on indices of disease activity in systemic sclerosis</title>
		<author>
			<persName><surname>Csrg)</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="93" to="98" />
			<date type="published" when="2007">2007</date>
		</imprint>
		<respStmt>
			<orgName>Canadian Scleroderma Research Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database</title>
		<author>
			<persName><forename type="first">C</forename><surname>Foocharoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Distler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Becker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="243" to="246" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Preliminary criteria for classification ofsystemic sclerosis (scleroderma)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Rodnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="581" to="590" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Steen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="84" to="88" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Echocardiography of the pulmonary circulation and right ventricular function: exploring the physiologic spectrum in 1480 normal subjects</title>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Andrea</forename><forename type="middle">A</forename><surname>Naeije</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Grunig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Caso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'alto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Palma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="1071" to="1078" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Standardization of Spirometry 1994 update</title>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="1107" to="1136" />
			<date type="published" when="1995">1995</date>
			<publisher>American Thoracic Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Single breath Carbon monoxide diffusing capacity ( transfer Factor)</title>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="2185" to="2198" />
			<date type="published" when="1995">1995</date>
			<publisher>American Thoracic Society</publisher>
		</imprint>
	</monogr>
	<note>Reccomendation of a standard technique-1995 update</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Classification Criteria for Systemic Sclerosis: An American College of Rheumatology-European League Against Rheumatism Collaborative Initiative</title>
		<author>
			<persName><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="2737" to="2747" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cutolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pizzorni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="155" to="160" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Assessment of disease severity and prognosis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Czirjak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scorza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Rossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bencivelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="S42" to="S4623" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl. 29</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Harel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iliescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baron</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician&apos;s Global Assessment of Disease Severity in Systemic Sclerosis</title>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">C</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fertig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Somogyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="104" to="109" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Autoantibodies in systemic sclerosis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Steen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="35" to="42" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The palpable tendon friction rub: an Important physical examination finding in patients with Systemic Sclerosis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Steen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1146" to="1151" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Hypocomplementemia in systemic sclerosis--clinical and serological correlations</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fritzler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="2218" to="2223" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres</title>
		<author>
			<persName><forename type="first">Della</forename><surname>Rossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="585" to="591" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Avouac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hachulla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2014-08-27">2014 Aug 27</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group</title>
		<author>
			<persName><forename type="first">C</forename><surname>Muangchan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khimdas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1405" to="1414" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Schnitzler Met al. The association between disease activity and duration in systemic sclerosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Steele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2299" to="2306" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Digital ulcers predict a worse disease course in patients with systemic sclerosis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mihai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2015-02-16">2015 Feb 16</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Tashkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Volkmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Tseng</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2014-206076</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2014-12-01">2014 Dec 1</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Wiese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Berrocal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1731" to="1739" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Disease activity criteria for patients with early systemic sclerosis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Diaconu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vonk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Denton</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">P275</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Construct validity of the European Scleroderma Study Group activity index and investigation of possible new disease activity markers in systemic sclerosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Minier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Nagy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Balint</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1133" to="1145" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Interstitial lung disease in systemic sclerosis: a simple staging system</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Goh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Desai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Veerarghavan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="1248" to="1254" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
